Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Takatsuki-shi, Osaka, Japan.
Institute for Integrated Radiation and Nuclear Science, Kyoto University, Osaka, Japan.
Med Phys. 2022 Aug;49(8):4944-4954. doi: 10.1002/mp.15823. Epub 2022 Jul 4.
Patients who undergo accelerator-based (AB) boron neutron capture therapy (BNCT) for head and neck cancer in the sitting position are generally uncomfortably immobilized, and patient motion during this treatment may be greater than that in other radiotherapy techniques. Furthermore, the treatment time of BNCT is relatively long (up to approximately 1 h), which increases the possibility of patient movement during treatment. As most BNCT irradiations are performed in a single fraction, the dosimetric error due to patient motion is of greater consequence and needs to be evaluated and accounted for. Several treatment parameters are required for BNCT dose calculation.
To investigate the dosimetric impacts (DIs) against position errors using a simple cylindrical phantom for an AB-BNCT system under different treatment parameter settings.
The treatment plans were created in RayStation and the dose calculation was performed using the NeuCure® dose engine. A cylindrical phantom (16 cm diameter × 20 cm height) made of soft tissue was modeled. Dummy tumors in the form of a 3-cm-diameter sphere were arranged at depths of 2.5 and 6.5 cm (denoted by T and T , respectively). Reference plans were created by setting the following parameters: collimator size = 10, 12, or 15 cm in diameter, collimator-to-surface distance (CSD) = 4.0 or 8.0 cm, tumor-to-blood ratio (T/B ratio) using F-fluoro-borono-phenylalanine = 2.5 or 5.0, and B concentration in blood = 20, 25, or 30 ppm. The prescribed dose was D ≥ 20 Gy-eq for both T and T . Based on the reference plans, phantom-shifted plans were created in 26 directions [all combinations of left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions) and three distances (1.0, 2.0, and 3.0 cm). The DIs were evaluated at D of the tumors. The shift direction dependency of the DI in the LR, AP, and SI directions was evaluated by conducting a multiple regression analysis (MRA) and other analyses where required.
The coefficients of the MRA of the DIs for LR, AP, and SI shifts were -0.08, 2.16, and -0.04 (p-values = 0.084, <0.01, and 0.334) for T and -0.05, 2.08, and 0.15 (p-values = 0.526, <0.01, and 0.065) for T , respectively. The analysis of variance showed that DIs due to the AP shift were significantly greater for smaller collimator sizes on T and smaller CSD on T . Dose reduction due to SI or LR (lateral) shifts was significantly greater for smaller collimator sizes on both T and T and smaller CSD on T , according to the Student's t-test. There were no significant differences in the DIs against both the AP shift and the lateral shift between the different T/B ratios and B concentrations.
The DIs were largely affected by the shift in the AP direction and were influenced by the different treatment parameters.
接受头部和颈部癌症的加速器硼中子俘获治疗(AB-BNCT)的患者在坐姿时通常会感到非常不适,并且在治疗过程中患者的运动可能比其他放射治疗技术更大。此外,BNCT 的治疗时间相对较长(长达约 1 小时),这增加了治疗过程中患者运动的可能性。由于大多数 BNCT 照射都是单次分割进行的,因此由于患者运动而导致的剂量误差更为重要,需要进行评估和考虑。BNCT 剂量计算需要几个治疗参数。
研究使用 AB-BNCT 系统的简单圆柱形体模在不同治疗参数设置下的位置误差的剂量学影响(DI)。
治疗计划在 RayStation 中创建,并使用 NeuCure®剂量引擎进行剂量计算。构建了一个软组织制成的直径为 16cm 高 20cm 的圆柱形体模。以 3cm 直径的球体形式布置了 dummy 肿瘤,深度分别为 2.5cm(记为 T)和 6.5cm(记为 T')。参考计划通过以下参数设置创建:准直器尺寸=10、12 或 15cm 直径、准直器到表面距离(CSD)=4.0 或 8.0cm、肿瘤与血液比(T/B 比)使用 F-氟代苯丙氨酸=2.5 或 5.0,以及血液中的 B 浓度=20、25 或 30ppm。对于 T 和 T',处方剂量均为 D≥20Gy-eq。基于参考计划,在 26 个方向(左右(LR)、前后(AP)和上下(SI)方向的所有组合)和三个距离(1.0、2.0 和 3.0cm)创建了体模移位计划。在肿瘤的 D 处评估 DI。通过进行多元回归分析(MRA)和其他需要的分析,评估了 LR、AP 和 SI 方向的 DI 方向依赖性。
T 上 LR、AP 和 SI 移位的 MRA 分析的 DI 系数分别为-0.08、2.16 和-0.04(p 值分别为 0.084、<0.01 和 0.334),T'上为-0.05、2.08 和 0.15(p 值分别为 0.526、<0.01 和 0.065)。方差分析表明,对于 T 上较小的准直器尺寸和 T 上较小的 CSD,AP 移位引起的 DI 显著更大。根据学生 t 检验,对于 T 和 T 上较小的准直器尺寸和 T 上较小的 CSD,由于 SI 或 LR(横向)移位引起的剂量减少显著更大。在不同的 T/B 比和 B 浓度下,AP 移位和侧向移位的 DI 之间没有显著差异。
DI 主要受 AP 方向移位的影响,并受不同治疗参数的影响。